Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer

Feng, Long-Hai; Qi, Qi; Wang, Peng; Chen, Hao; Chen, Zheng; Meng, Zhiqiang; Liu, Luming

doi:10.1177/0300060518800588

Cited by 92 publications

(69 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results in (Figure 1) showed a signi icant increase [p<0.001, p<0.002, p<0.01] in the level of interleukins (IL-4, IL-6, IL-8) in ovarian cancer patients compared to the healthy control group. These results were in agreement with those performed by others (Feng et al, 2018) which they found that serum interleukins increased in cancer patients compared to normal ones. A large number of studies propose that factors linked to the in lammation of the ovarian surface epithelium are correlated with an elevated risk for epithelial ovarian cancer (EOC).…”

Section: Resultssupporting

confidence: 93%

Variation of Serum Interleukin, Gonadotropins hormone and Steroid hormone levels in women with Ovarian Cancer

Ali¹,

Ismail²

2020

ijrps

View full text Add to dashboard Cite

Ovarian cancer has high mortality and delayed diagnosis. Inflammation is considered as a risk for ovarian carcinoma, and it contributes to all grades of tumour progression. Inflammation involved in the development of cancer cell and can be caused by an increase in the formation of pro-inflammatory cytokines. This research was conducted to assess serum Interleukin, Gonadotropins hormone and Steroid hormone levels in ovarian cancer patients and to assess their impact in disease action. The present study is composed of 85 women (mean age = 62.03±12.4 yrs) with clinically and pathologically confirmed ovarian cancer and 65 healthy women as a control group (mean age = 61±12.1 yrs). The measured biochemical parameters included: the level of serum gonadotropins(LH, luteinizing hormone; FSH, follicle-stimulating hormone), steroid hormones (estrogen, progesterone, prolactin, testosterone) and Interleukin (IL-4, IL-6, and IL-8). The results demonstrated significantly high values of steroid hormones (p<0.01, p<0.01, p<0.05,p<0.002, p<0.01 (estrogen, progesterone, prolactin, testosterone) and significantly high ( p<0.001, p<0.002, p<0.01)values in (IL-4, IL-6, and IL-8) in ovarian cancer in comparison with control group. There were also significantly high (p<0.0001, p<0.05 values of sera LH and FSH in women ovarian cancer in comparison with the control group. p<0.01, p<0.001) respectively in ovarian cancer in comparison with the control group. An elevation of serum steroid hormone, gonadotropins, and Interleukin levels in cases of ovarian carcinoma in our study is important as a marker of the disease.

show abstract

Section: Resultssupporting

confidence: 93%

Variation of Serum Interleukin, Gonadotropins hormone and Steroid hormone levels in women with Ovarian Cancer

Ali¹,

Ismail²

2020

ijrps

View full text Add to dashboard Cite

show abstract

“…Elevation of serum IL-6 is a negative prognostic marker in human PDAC Serum IL-6 levels were increased in PDAC patients compared with healthy patients [69,[152][153][154][155][156][157][158] or those with chronic pancreatitis [152,154,157,158], and were also increased in patients with metastatic PDAC compared to those with locally advanced disease [157][158][159][160][161]. Moreover, elevated serum IL-6 positively correlated with increased disease burden, weight loss/cachexia, and metastasis [69,[152][153][154][155][156][157][158][159][160][162][163][164][165][166][167], however, there are conflicting observations in the literature regarding IL-6 and cachexia [161]. Although, increased serum IL-6 levels correlate with increased disease stage, and in metastatic patients correlates with poor overall survival [161,168].…”

Section: Interleukin 6 In Pdacmentioning

confidence: 99%

Emerging roles for the IL-6 family of cytokines in pancreatic cancer

2020

View full text Add to dashboard Cite

Pancreatic cancer has one of the poorest prognoses of all malignancies, with little improvement in clinical outcome over the past 40 years. Pancreatic ductal adenocarcinoma is responsible for the vast majority of pancreatic cancer cases, and is characterised by the presence of a dense stroma that impacts therapeutic efficacy and drives pro-tumorigenic programs. More specifically, the inflammatory nature of the tumour microenvironment is thought to underlie the loss of anti-tumour immunity and development of resistance to current treatments. Inflammatory pathways are largely mediated by the expression of, and signalling through, cytokines, chemokines, and other cellular messengers. In recent years, there has been much attention focused on dual targeting of cancer cells and the tumour microenvironment. Here we review our current understanding of the role of IL-6, and the broader IL-6 cytokine family, in pancreatic cancer, including their contribution to pancreatic inflammation and various roles in pancreatic cancer pathogenesis. We also summarise potential opportunities for therapeutic targeting of these pathways as an avenue towards combating poor patient outcomes.

show abstract

“…IL-8 was first discovered as a leukocyte chemotactic factor and since then emerged as a double-edged sword of inflammation (Beck et al, 2016;Hammond et al, 1995;Long et al, 2016;Sallusto and Baggiolini, 2008;Singer and Sansonetti, 2004). Further, IL-8 has emerged as a crucial factor in mediating tumour angiogenesis, tumour cell survival and metastasis (David et al, 2016;Feng et al, 2018;Itoh et al, 2005;Li et al, 2003;Waugh and Wilson, 2008;Xu and Fidler, 2000). Intriguingly, the effect is kinase-independent and we demonstrated that ERK3 controls the transcription factor AP-1/c-Jun in both, HCPECs and HT-29 cells ( Figure 6D-6E and Figure 6G, respectively).…”

Section: Discussionmentioning

confidence: 99%

ERK3/MAPK6 controls IL-8 production and chemotaxis

Bogucka

Pompaiah

Marini

et al. 2020

eLife

View full text Add to dashboard Cite

ERK3 is a ubiquitously expressed member of the atypical mitogen activated protein kinases (MAPKs) and the physiological significance of its short half-life remains unclear. By employing gastrointestinal 3D organoids, we detect that ERK3 protein levels steadily decrease during epithelial differentiation. ERK3 is not required for 3D growth of human gastric epithelium. However, ERK3 is stabilized and activated in tumorigenic cells, but deteriorates over time in primary cells in response to lipopolysaccharide (LPS). ERK3 is necessary for production of several cellular factors including interleukin-8 (IL-8), in both, normal and tumorigenic cells. Particularly, ERK3 is critical for AP-1 signaling through its interaction and regulation of c-Jun protein. The secretome of ERK3-deficient cells is defective in chemotaxis of neutrophils and monocytes both in vitro and in vivo. Further, knockdown of ERK3 reduces metastatic potential of invasive breast cancer cells. We unveil an ERK3-mediated regulation of IL-8 and epithelial secretome for chemotaxis.

show abstract

Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer

Cited by 92 publications

References 42 publications

Variation of Serum Interleukin, Gonadotropins hormone and Steroid hormone levels in women with Ovarian Cancer

Variation of Serum Interleukin, Gonadotropins hormone and Steroid hormone levels in women with Ovarian Cancer

Emerging roles for the IL-6 family of cytokines in pancreatic cancer

ERK3/MAPK6 controls IL-8 production and chemotaxis

Contact Info

Product

Resources

About